Evidence map›Paper›PMID 42238637›Full record

ReviewReviews in cardiovascular medicine2026

Technological Innovations and Research Frontiers in Interventional Therapy for Mitral Regurgitation.

Shuang Wang, Aili Wang, Yuna Huang, Jinping Liu, Bin Wang

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuang WangDepartment of Cardiovascular Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan University, 430071 Wuhan, Hubei, China.ORCID https://orcid.org/0009-0004-8148-7152
Aili WangDepartment of Cardiovascular Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan University, 430071 Wuhan, Hubei, China.
Yuna HuangDepartment of Cardiovascular Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan University, 430071 Wuhan, Hubei, China.
Jinping LiuDepartment of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, 430071 Wuhan, Hubei, China.
Bin WangDepartment of Cardiovascular Ultrasound, Zhongnan Hospital of Wuhan University, Wuhan University, 430071 Wuhan, Hubei, China.ORCID https://orcid.org/0000-0003-0201-9154

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitral regurgitation (MR) is a common valvular heart diseasewhose prevalence continues to increase with population aging, posing a serious threat to human health in the advanced stages of the disease. Sole reliance on medication and traditional surgical treatments can no longer meet the therapeutic needs of all patients. Transcatheter interventional therapy is gradually emerging as a promising new treatment option. Recently, technologies for the transcatheter interventional treatment of MR have advanced rapidly, with expanding indications and a continuous stream of new devices. The field has entered a phase of accelerated development in the treatment of structural heart disease, demonstrating broad clinical prospects. This article reviews the key technologies and developmental trends in the current transcatheter interventional treatments for MR, aiming to provide a theoretical basis and rationale for the safe and standardized implementation and broader adoption of these technologies.

Indexed as

medical devicesmitral regurgitationstructural heart diseasetranscatheter intervention

Identifiers

PMID42238637
PMCPMC13227383

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.